Dongcheng Pharmaceutical announced that the holding subsidiary Zhongtai Biotech underwent on-site inspections by the US Food and Drug Administration from July 17 to July 18, 2026. Recently, it received an on-site inspection report issued by the FDA and passed the on-site inspection with zero “483” NAI defects.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.